Campbell, Andrew D. http://orcid.org/0000-0002-8829-0043
Colombatti, Raffaella
Andemariam, Biree
Strunk, Crawford
Tartaglione, Immacolata
Piccone, Connie M.
Manwani, Deepa
Asare, Eugenia Vicky
Boruchov, Donna
Farooq, Fatimah
Urbonya, Rebekah
Boatemaa, Gifty Dankwah
Perrotta, Silverio
Sainati, Laura
Rivers, Angela
Rao, Sudha
Zempsky, William
Sey, Fredericka
Segbefia, Catherine
Inusa, Baba
Antwi-Boasiako, Charles
Funding for this research was provided by:
National Institute on Minority Health and Health Disparities (T37MD001425)
Article History
Received: 19 January 2020
Revised: 6 April 2020
Accepted: 13 April 2020
First Online: 16 May 2020
Compliance with Ethical Standards
:
: A Campbell: research funding and consultancy from Global Blood Therapeutics (GBT), Novartis, Cyclerion; consultancy from BluebirdBio; D Manwani: research funding from Grifols; consultancy for Novartis, Pfizer, Global Blood Therapeutics; B Andemariam: consultancy for Novartis, Pfizer, NovoNordisk, Emmaus, Cyclerion, Terumo, Sanofi; DSMB: Global Blood Therapeutics; research funding: Imara; B Inusa: education funding: Novartis AstraZeneca, Global Blood Therapeutics, Celgene, Vertex; C. Strunk: consultancy Global Blood Therapeutics and Novartis; R Colombatti: research funding: Global Blood Therapeutics, Novartis. No disclosures to declare from the other co-authors.
: Except at two sites (Guys and St Thomas Hospital, UK; Azienda Ospedaliera-Università di Padova, Italy) that had a previously Institutional Review Board–approved Sickle Cell Disease Registry, Institutional Review Board approval was obtained at each site and written informed consent was obtained by each patient and/or parent/guardian.